Alnylam Pharmaceuticals Inc (ALNY)
245.50
+6.63
(+2.78%)
USD |
NASDAQ |
Dec 20, 16:00
245.46
-0.04
(-0.02%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value: 29.91B for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc | 206.32B |
| BridgeBio Pharma Inc | 6.472B |
| Gilead Sciences Inc | 133.49B |
| Regeneron Pharmaceuticals Inc | 69.31B |
| Sarepta Therapeutics Inc | 11.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.57M |
| Revenue (Quarterly) | 500.92M |
| Total Expenses (Quarterly) | 577.82M |
| EPS Diluted (Quarterly) | -0.87 |
| Gross Profit Margin (Quarterly) | 82.85% |
| Profit Margin (Quarterly) | -22.27% |
| Earnings Yield | -1.07% |
| Normalized Earnings Yield | -0.7489 |